ClinicalTrials.gg
RecruitingNCT07633236Updated Jun 8, 2026

Olanzapine in the Prevention and Treatment of Anorexia-Cachexia Syndrome in Patients Receiving Neoadjuvant/Preoperative Chemotherapy

A Phase 3 interventional study of OLANZapine 2.5 MG in Oncology Patients Receiving Chemotherapy, Cachexia-Anorexia Syndrome and Oncology, sponsored by Blokhin's Russian Cancer Research Center. Recruiting at 1 site in Russia. Per ClinicalTrials.gov, last updated 2026-06-08.

Sponsored by Blokhin's Russian Cancer Research Center · Phase 3, Interventional, and Supportive care

How we know

From the registry’s dates

  • Registered 1 year 2 months after the study started (first participant enrolled Mar 2025, registered Jun 2026).
  • Started Mar 2025; still recruiting 1 year 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
100
Allocation
Randomized
Sex
All
01

Study summary

The goal of this clinical trial is to learn if olanzapine works to prevent and treat anorexia-cachexia syndrome and appetite loss in cancer patients. The main questions it aims to answer are:

Is prolonged low-dose olanzapine effective and save in:

  • Preventing/treating weight loss due to anorexia.
  • Controlling nausea/vomiting.
  • Maintaining anticancer therapy dose intensity?

Does prolonged low-dose olanzapine improve quality of life in patients receiving neoadjuvant/preoperative chemotherapy?

Participants will:

Take prolonged low-dose olanzapine (2.5 mg/day) in treatment group or usual diet only in control group until surgical treatment Physical examination, anthropometric assessment, blood tests, quality of life, appetite and nutritional status assessment, abdominal CT, handgrip dynamometry before chemotherapy and after preoperative chemotherapy before surgery Physical examination, adverse events every visit Surgical complications within 30 days after surgery

02

Conditions studied

  • Oncology Patients Receiving Chemotherapy
  • Cachexia-Anorexia Syndrome
  • Oncology

Browse trials for

03

In context

Neoplasms

10,838 studies on the registry are indexed under Neoplasms; 2,322 are open to participants now.

This study's planned enrollment of 100 is above the median of 60 across 7,716 interventional studies indexed under Neoplasms.

Browse Neoplasms studies →

Lead sponsor

Blokhin's Russian Cancer Research Center is the lead sponsor of 34 studies on the registry; 17 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥18 years
  • status 0-2
  • Localized/locally advanced ovarian or gastric cancer requiring /preoperative chemotherapy followed by surgery
  • Ability to consume food/medications orally

Exclusion criteria

Exclusion Criteria:

  • Olanzapine use (>4 days) for other indications at enrollment
  • Current use of antipsychotics/antidepressants
  • Systemic use (>7 days within the last 4 weeks)
  • History of psychiatric disorders
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 3
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
100 participants (estimated)

Study arms

  • Experimental
    treatment

    Drug: OLANZapine 2.5 MG

  • No intervention
    control

Interventions

06

What researchers measure

Primary outcomes

  1. Proportion of patients with ≤5% weight loss

    Time frame: from enrollment to the end of preoperative chemotherapy

07

Study locations

1 of 1 sites recruiting
  • Federal State Budgetary Institution "N.N. Blokhin National Medical Research Center of Oncology" оf the Ministry of Health of the Russian Federation
    Moscow, Russia
    Recruiting
    • Olga Palchinskaia · Contactkfoli@mail.ru · +7 916 991 06 23
08

References and documents

Individual participant data

Plan to share: Yes — all IPD collected throughout the trial

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: 14/05/2026 - indefinitely

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2025 (actual). Primary completion is estimated for Dec 2026, 21 months after the start.

Of 83 non-industry phase 3 interventional studies under Neoplasms, half reached primary completion within 60 months of starting (the median), counting those still running; a quarter within 43 and three quarters within 96. This study's planned 21 months is below that.

Counting every sponsor, half of 203 studies reached it within 50 months; a quarter within 33 and three quarters within 84.

Neoplasms covers many different conditions, not one, so the studies compared here vary widely. Read these figures as a rough guide.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 3, 2026
First posted
Jun 8, 2026
StartActual
Mar 28, 2025
Primary completionEst.
Dec 28, 2026
CompletionEst.
May 31, 2027
Last update
Jun 8, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 8, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07633236
Lead sponsor
Blokhin's Russian Cancer Research Center
Responsible party
Sponsor
First posted
Jun 8, 2026
Start date
Mar 28, 2025
Primary completion
Dec 28, 2026 (estimated)
Completion
May 31, 2027 (estimated)
Last update
Jun 8, 2026

Study contacts

Olga Palchinskaia
Contact
kfoli@mail.ru
+7 916 991 06 23

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Olanzapine

Start the discussion